Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

November 2007, Regeneron Pharmaceuticals ($REGN @Regneron) entered into a global, strategic collaboration with Sanofi ($SNY @Sanofi) to discover, develop, and commercialize fully human monoclonal antibodies (the “Antibody Collaboration”). The Antibody Collaboration is governed by the companies’ Discovery and Preclinical Development Agreement (“Antibody Discovery Agreement”) and a License and Collaboration Agreement. Upfront Payment $85MM for Regeneron […]

July 2013, Array BioPharma (ARRY) and Celgene Corporation (CELG) and Celgene Alpine Investment Co., LLC (collectively “Celgene”) entered into a Drug Discovery and Development Option and License Agreement to collaborate on development of an Array invented preclinical development program targeting a novel inflammation pathway. The agreement provides Celgene an option to select multiple clinical development […]

TxCell (France), a clinical-stage biotechnology developing cell-based immunotherapies for chronic inflammatory and neurological diseases, closed a $15.9M Series C financing. Participants include CDC Entreprises, Auriga Partners and Seventure Partners. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP […]

CytoPherx (Ann Arbor, MI) a clinical-stage medical device company focused on dialysis filters to sequester and deactivate leukocytes in the patient’s blood system for acute renal failure, closed a $34M Series C financing. Participants include Early Stage Partners, Onset Ventures and Capital Midwest Fund.

CytoPherx (Ann Arbor, MI) a clinical-stage medical device company focused on dialysis filters to sequester and deactivate leukocytes in the patient’s blood system for acute renal failure, closed a $34M Series C financing. Participants include Early Stage Partners, Onset Ventures and Capital Midwest Fund.

Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

Apogenix (Germany) a clinical-stage biopharmaceutical company focused on modulators of apoptosis and IL-4 signaling for glioblastoma and other cancers, graft versus host disease and inflammatory diseases, closed a $10M Series C financing. Participants include Dievini Hopp BioTech.

Syndexa Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on enzyme inhibitors for Alzheimer’s disease and inflammatory diseases, closed a $8.5M Series B financing. Participants include MP Healthcare Venture Management.

Probiodrug (Germany) a clinical-stage biopharmaceutical company focused enzyme inhibitors for Alzheimer’s and inflammatory disease, closed a $20M Series C financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Sciences Partners, Biogen Idec New Ventures, TVM Capital, HBM BioVentures, Goodvent and Wellington Management Company.

Dermira (Redwood City, CA) a clinical-stage pharmaceutical company focused on topical treatments and light therapy for acne and inflammatory skin disease, closed a $42M Series A financing. Participants include Bay City Capital, New Enterprise Associates and Canaan Partners.

Creabilis (Luxembourg) a clinical-stage biotechnology company focused dermatology and inflammatory diseases, closed a $20M Series B financing. Participants include Abbott Biotech Ventures, Neomed and Sofinnova Partners.

Bind Biosciences (Cambridge, MA) a clinical-stage biopharmaceutical company focused on new class of highly selective targeted chemotherapeutic nano-therapeutics for solid tumors, closed a $25.5M Series D financing. Participants include Rusnano.

Catabasis Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on fatty acid conjugated compounds for severe hypertriglyceridemia, diabetes, inflammatory and metabolic diseases, closed a $8M Series A financing bringing total round to $47.6M. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

« Previous Entries  Next Page »

to top of page...